LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Начало・Списък с акции・Vaxart Inc

Vaxart Inc

Затворен

0.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.32

Максимум

0.32

Ключови измерители
By Trading Economics
Приходи	6.8M -8.1M
Продажби	33M 72M
EPS	-0.04
Марж на печалбата	-11.242
Служители	105
EBITDA	6.7M -5.4M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-2.5M 89M
Предишно отваряне	0.32
Предишно затваряне	0.32

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.4007 / 0.4252 Подкрепа & съпротива

Vaxart Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.12.2025 г., 16:42 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

12.12.2025 г., 23:49 ч. UTC

Придобивния, сливания и поглъщания

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12.12.2025 г., 22:52 ч. UTC

Пазарно говорене

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12.12.2025 г., 22:32 ч. UTC

Печалби

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.12.2025 г., 20:45 ч. UTC

Печалби

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12.12.2025 г., 20:41 ч. UTC

Пазарно говорене

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12.12.2025 г., 20:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12.12.2025 г., 19:23 ч. UTC

Печалби

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12.12.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12.12.2025 г., 18:33 ч. UTC

Придобивния, сливания и поглъщания

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12.12.2025 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12.12.2025 г., 17:49 ч. UTC

Печалби

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12.12.2025 г., 17:34 ч. UTC

Придобивния, сливания и поглъщания

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12.12.2025 г., 17:33 ч. UTC

Придобивния, сливания и поглъщания

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12.12.2025 г., 17:33 ч. UTC

Придобивния, сливания и поглъщания

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12.12.2025 г., 17:32 ч. UTC

Придобивния, сливания и поглъщания

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12.12.2025 г., 17:31 ч. UTC

Придобивния, сливания и поглъщания

Orange to Buy the Stake for EU4.25B in Cash

12.12.2025 г., 17:24 ч. UTC

Пазарно говорене

Argentina Predicts Record Wheat Crop -- Market Talk

12.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

12.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.12.2025 г., 17:18 ч. UTC

Пазарно говорене

Печалби

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12.12.2025 г., 17:09 ч. UTC

Пазарно говорене

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12.12.2025 г., 17:09 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

12.12.2025 г., 16:47 ч. UTC

Пазарно говорене

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

12.12.2025 г., 16:39 ч. UTC

Пазарно говорене

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

12.12.2025 г., 16:27 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725M Deal for Liquid Nails From PE Firm -- 2nd Update

12.12.2025 г., 16:15 ч. UTC

Печалби

At Costco, Lots of Pie but No Special Dividend. Why the Street Didn't Like the Earnings. -- Barrons.com

12.12.2025 г., 15:35 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12.12.2025 г., 14:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Vaxart Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Vaxart Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.4007 / 0.4252Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.